Establishment Labs Holdings Inc. is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.
The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification. In addition to its core breast implant offerings, Establishment Labs is actively advancing a pipeline of complementary aesthetic and regenerative technologies aimed at expanding its footprint in minimally invasive and soft-tissue restoration procedures.
Founded in Costa Rica in 2004, Establishment Labs has grown into an international enterprise with manufacturing facilities in Central America and distribution in more than 70 markets across North America, Latin America, Europe and the Asia-Pacific region. The company further broadened its capital access through a special purpose acquisition merger, resulting in its listing on the Nasdaq exchange in mid-2020.
Leadership is anchored by founder and Executive Chairman Mauricio Cárdenas, whose entrepreneurial vision has guided the company since inception, alongside Chief Executive Officer Juan José Chacón, who oversees global operations, strategy and continued product innovation.
AI Generated. May Contain Errors.
